Inspired by Rebecca

Customers regularly reach out to me to give me feedback about our therapies. I recently received the testimonial below and it warmed my heart, so I thought I would share it with you.

My name is Rebecca and I’ve had T1 for 32 years. I was diagnosed at the age of 4 and remember the experience quite vividly.  I remember the thirst, the sickness, and needing to use the restroom all the time.  I remember waking up in the hospital and being told I could no longer have sugar in my cheerios. The pink “sugar” packet they gave me was terrible!

My family was the most supportive a child with T1 could ask for. Back then, my meter was huge, and my insulin was beyond temperamental.  I would have to eat snacks, even though I wasn’t hungry. I would have to drink soda while having the stomach flu because I had to take my insulin injections.

When I was 15, I started on my first insulin pump. I believe it was the MiniMed™ 507 system. It was a life changer. If I was ill and vomiting, I didn’t have to eat a snack — I could adjust my basal. I could hang out with my friends and have some ice cream if I wanted. Through the years, I have tried different pumps and I’ve tried professional continuous glucose monitoring (CGM). I went to nursing school then decided to become a Certified Diabetes Educator (CDE) because I couldn’t stand it when people who didn’t have the disease would tell me what to do.  I want to give other people living with diabetes hope because I didn’t have complications.

My life has been a life of worry and fear. I had my last severe low a few years ago and was so scared. The thought of complications such as early dementia, heart attack, dialysis, etc. due to diabetes keeps me up at night. All my life, I would pray that something, anything, would be developed to help keep me alive so that I can be with my family longer.

Then the Medtronic MiniMed™ 670G came along. This was a game changer! I cried when I was told I was part of the first group that received the therapy and cried the first time I saw the blue SmartGuard™ shield. I went for a run and didn’t get below 65 mg/dl. I could play basketball with my stepdaughters and not worry. I am getting teary eyed just thinking about it. Out of habit, I wake up in the middle of the night to check which way my glucose is going, but then I see the blue SmartGuard™ shield and I fall back asleep. I can honestly say that I sleep restfully now.

I want to thank all the scientists and engineers who developed this product. I want to thank Medtronic for getting it to market and approved by insurance. It’s because of Medtronic that I can continue to live my life without complications, and be around for many years to raise my 11-month old daughter. Thank you!

Rebecca

 

IMPORTANT SAFETY INFORMATION

The Medtronic MiniMed™ 670G system requires a prescription and is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of Type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G System includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values.

The Guardian™ Sensor (3) is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian™ Sensor (3).

WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Do not use the serter on products other than the Enlite™ sensor or Guardian™ Sensor (3). Medtronic cannot guarantee the safety or efficacy of this product if used with other products. The reservoir is contraindicated for the infusion of blood or blood products.

Infusion sets are indicated for subcutaneous use only and not for intravenous (IV) infusion or the infusion of blood or blood products. Insulin pump therapy is not recommended for those who are unwilling to perform at least four blood glucose tests per day. As insulin pumps use rapid acting insulin only, BG testing is required to help identify rapid glycemic deterioration due to insulin infusion occlusion, infusion site problems, insulin stability issues, user error, or a combination of these. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional.

The safety of the 670G system has not been studied in people with impaired kidney function. Please let your healthcare professional know if you have kidney disease so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks. The safety of the 670G system has not been studied in pregnant women, people with type 2 diabetes, or in people using other anti-hyperglycemic therapies apart from insulin. Please let your healthcare professional know if any of these conditions apply to you so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks.

For complete safety information, please consult the appropriate User Guide.

Print This Post Print This Post

Post A Comment

Your email address will not be published. Required fields are marked *